Market revenue in 2023 | USD 83.0 million |
Market revenue in 2030 | USD 129.9 million |
Growth rate | 6.6% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 58.31% in 2023. Horizon Databook has segmented the Brazil biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil scientific literature output is already on par with EU countries, such as Switzerland, Sweden, Holland, and Russia. The Brazilian government has taken concrete steps to improve co-operation between universities and industry. This step encourages setting of R&D industry, as 27% of patents in Brazil are owned by public universities.
According to Outsourcing-Pharma.com, 50% of the Latin America clinical trials are taking place in Brazil. Another article published by outsourcing pharma stated that lower cost of clinical study and testing might drive the CRO market in the country.
However, regulatory issues have restrained the clinical development, which in turn, is limiting growth of CDMOs in the country. Bottlenecks in Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) submission and approval protocol result in longer approval duration. These factors might impede market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into Brazil biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account